Form D · Pharmaceuticals
AKCEA THERAPEUTICS, INC.
Cambridge, MA · CIK 0001662524
Offering snapshot reported Jan 4, 2016 · SEC filing
- Reported sold
- $543M Offering amount: $543M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 18, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 4, 2016 | Initial | $543,168,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-254386
Includes cash and non-cash consideration, including the grant of certain rights and licenses to the Issuer.
Source: Form D, filed Jan 4, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stanley T. Crooke | Director, Executive |
| Jeffrey Goldberg | Executive |
| Elizabeth L. Hougen | Executive |
| Patrick O'neil | Executive |
| B. Lynne Parshall | Director |
| Paula Soteropoulos | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
55 Cambridge Parkway Suite 100
Cambridge, MA, 02142
Cambridge, MA, 02142